Efficacy and ctDNA analysis in an updated cohort of patients with TRK fusion lung cancer treated with larotrectinib

被引：0

作者：

Hoejgaard, M. ^{[1
]}

Drilon, A. ^{[2
,3
]}

Lin, J. J. ^{[4
]}

Kummar, S. ^{[5
]}

Tan, D. S. W. ^{[6
]}

Patel, J. ^{[7
]}

Leyvraz, S. ^{[8
]}

Garcia, V. Moreno ^{[9
]}

Rosen, L. S. ^{[10
]}

Solomon, B. ^{[11
]}

Yachnin, J. ^{[12
]}

Liu, Y. ^{[13
,14
]}

Dai, M-S. ^{[15
]}

Norenberg, R. ^{[16
]}

Burcoveanu, D-I. ^{[17
]}

Yun, L. ^{[18
]}

Beckmann, G. ^{[19
]}

Mussi, C. E. ^{[20
]}

Shen, L. ^{[21
]}

机构：

[1] Rigshosp, Dept Oncol, Phase Unit 1, Copenhagen, Denmark

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Weill Cornell Med Coll, New York, NY USA

[4] MGH Massachusetts Gen Hosp, Thorac Oncol Dept, Boston, MA USA

[5] OHSU Knight Canc Inst, Div Hematol & Med Oncol, Ctr Hlth & Healing, Bldg 1 South Waterfront, Portland, OR USA

[6] NCCS Natl Canc Ctr Singapore, Med Oncol Dept, Singapore, Singapore

[7] Northwestern Univ, Dept Med, Chicago, IL USA

[8] Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany

[9] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD Early Phase Clin Trials Unit, Madrid, Spain

[10] UCLA, Hematol Oncol Santa Monica, Santa Monica, CA USA

[11] Avera Canc Inst, Div Hematol & Oncol, Sioux Falls, SD USA

[12] Karolinska Univ Hosp, Dept Oncol, Solna, Sweden

[13] Sichuan Univ, West China Hosp, Ctr Canc, Dept Thorac Oncol, Chengdu, Peoples R China

[14] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China

[15] Tri Serv Gen Hosp, Divis Oncol, Taipei, Taiwan

[16] Chrestos Concept GmbH & Co KG, Stat, Essen, Germany

[17] Bayer Healthcare Pharmaceut Inc, Med Affairs Oncol, Basel, Switzerland

[18] Bayer HealthCare Pharmaceut Inc, Mississauga, ON, Canada

[19] Bayer AG Pharmaceut, Res & Dev Pharmaceut, Berlin, Germany

[20] Bayer SpA, Div Pharmaceut, Milan, Italy

[21] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

15MO

引用

页码：S48 / S49

页数：2

共 50 条

[31] Long-term efficacy and safety of larotrectinib in patients with TRK fusion-positive lung cancer.
Lin, Jessica Jiyeong
Kummar, Shivaani
Tan, Daniel Shao-Weng
Lassen, Ulrik Niels
Leyvraz, Serge
Liu, Yongmei
Moreno, Victor
Patel, Jyoti D.
Rosen, Lee S.
Solomon, Benjamin Maurice
Norenberg, Ricarda
Dima, Laura
Brega, Nicoletta
Shen, Lin
Drilon, Alexander E.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[32] Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials.
Kummar, Shivaani
Shen, Lin
Van Tilburg, Cornelis Martinus
Tan, Daniel S. W.
Doz, Francois
McDermott, Raymond S.
Zwaan, C. Michel
Keating, Karen N.
Chirila, Costel
Norenberg, Ricarda
Fellous, Marc Mardoche
Brega, Nicoletta
Xu, Rui-Hua
Laetsch, Theodore Willis
Drilon, Alexander E.
Hong, David S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[33] Long-term outcomes of patients with TRK fusion cancer treated with larotrectinib.
Drilon, Alexander
Kummar, Shivaani
Albert, Catherine M.
Nagasubramanian, Ramamoorthy
Hechtman, Jaclyn F.
Reeves, John A.
Beckmann, Georg
Rudolph, Marion
Wierzbinska, Justyna A.
Dima, Laura
Brega, Nicoletta
Laetsch, Theodore W.
Hong, David S.
CANCER RESEARCH, 2021, 81 (13)
[34] Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer
Brose, M. S.
Shen, L.
Tan, D. S. W.
Kummar, S.
Lin, J. J.
McDermott, R.
Berlin, J.
Tahara, M.
Lassen, U. N.
Leyvraz, S.
Patel, J. D.
Norenberg, R.
Dima, L.
Brega, N.
Hong, D. S.
Drilon, A.
ANNALS OF ONCOLOGY, 2021, 32 : S600 - S601
[35] Rationale and design of ON TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib
Yang, James C. H.
Brose, Marcia S.
Castro, Gilberto
Kim, Edward S.
Lassen, Ulrik N.
Leyvraz, Serge
Pappo, Alberto
Lopez-Rios, Fernando
Reeves, John A.
Fellous, Marc
Penault-Llorca, Frederique
Rudzinski, Erin R.
Tabatabai, Ghazaleh
Vassal, Gilles
Drilon, Alexander
Trent, Jonathan
BMC CANCER, 2022, 22 (01)
[36] Larotrectinib Demonstrates Durable Efficacy and Safety in an Expanded Dataset of Pediatric Patients with TRK Fusion Cancer
Koga, Yuhki
PEDIATRIC BLOOD & CANCER, 2021, 68
[37] Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer
Leyvraz, S.
Hong, D. S.
Shen, L.
van Tilburg, C. M.
Tan, D. S. W.
Kummar, S.
Lin, J. J.
Doz, F.
McDermott, R.
Albert, C. M.
Berlin, J.
Bielack, S.
Lassen, U. N.
Tahara, M.
Norenberg, R.
Shurshalina, A.
Fellous, M.
Nogai, H.
Xu, R.
Laetsch, T. W.
Drilon, A.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 13 - 13
[38] Larotrectinib Demonstrates Durable Efficacy and Safety in an Expanded Dataset Of Pediatric Patients With TRK Fusion Cancer
Mascarenhas, L.
Albert, C.
Pappo, A.
Geoerger, B.
Doz, F.
Federman, N.
Nagasubramanian, R.
Bielack, S.
Dubois, S.
Morgenstern, D.
Schulte, J.
Shukla, N.
Reeves, J.
De La Cuesta, E.
Dima, L.
Childs, B.
Laetsch, T.
Van Tilburg, C. M.
PEDIATRIC BLOOD & CANCER, 2020, 67 : S51 - S51
[39] ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer
Leyvraz, S.
Yang, J. C-H.
Casali, P. G.
Castro, G.
Kim, E. S.
Lassen, U. N.
Lopez-Rios, F.
Penault-Llorca, F.
Pappo, A.
Rudzinski, E. R.
Tabatabai, G.
Vassal, G.
Reeves, J. A.
Nogai, H.
Fellous, M.
Drilon, A.
Brose, M. S.
Trent, J.
ANNALS OF ONCOLOGY, 2020, 31 : S503 - S503
[40] EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN UPDATED ANALYSIS
Perreault, Sebastien
Doz, Francois
Geoerger, Birgit
Italiano, Antoine
Lassen, Ulrik
Nilsson, Anna
Nysom, Karsten
Spano, Jean-Philippine
Norenberg, Ricarda
Bernard-Gauthier, Vadim
de la Cuesta, Esther
Drilon, Alexander
Laetsch, Theodore
van Tilburg, Cornelis
NEURO-ONCOLOGY, 2023, 25

← 1 2 3 4 5 →